Cardiomyocyte Regulatory Elements Enhance Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy for cardiovascular diseases and muscle disorders is inefficient due to limitations in gene delivery and expression in heart and muscle cells, with conventional vector designs resulting in sub-optimal expression in target tissues.
Innovation Solution
The development of cardiomyocyte-derived cis-regulatory modules (CARD-CREs) that enhance gene expression in cardiomyocytes and skeletal muscle cells, using specific nucleic acid regulatory elements to maximize transgene expression and reduce vector doses required for therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vector designs are used for gene therapy, then delivery to heart and muscle cells is achieved, but gene expression in target tissues is sub-optimal
Solution Approach 1:
The patent applies local quality by developing cardiomyocyte-specific cis-regulatory modules (CARD-CREs) that are uniquely adapted to function in heart and muscle cells. These CREs contain specific transcription factor binding sites (e.g., MyoD1, Myogenin, MEF2) that are locally relevant to cardiomyocytes, enabling high-level gene expression specifically in target tissues while avoiding off-target expression in other organs.
Solution Approach 2:
The invention uses composite materials by combining multiple cis-regulatory elements into chimeric CREs that integrate functions from different natural promoters. The CARD-CREs are composite structures merging enhancer and promoter activities, creating a synergistic regulatory system that achieves superior gene expression compared to individual conventional promoters alone.
2Productivity
If higher vector doses are used to improve gene expression, then therapeutic effects are enhanced, but safety and off-target expression increase
Solution Approach 1:
The CARD-CREs provide local quality through their cardiomyocyte-specific transcription factor binding sites, which naturally restrict gene expression to heart and muscle tissues. This intrinsic tissue specificity allows achieving high gene expression levels without requiring excessive vector doses, thereby preventing off-target expression and reducing safety concerns associated with high-dose administration.
3Ease of manufacture
If conventional promoters are used, then gene delivery is simplified, but gene expression in cardiomyocytes is insufficient
Solution Approach 1:
The patent applies segmentation by dividing the complex regulatory function into distinct modular components within the CARD-CRE structure. Each module contains specific transcription factor binding sites (e.g., MyoD1 site, Myogenin site, MEF2 site) that can be independently identified and combined. This modular approach maintains ease of manufacture through standardized cloning while achieving superior cardiomyocyte-specific expression through the synergistic combination of segmented regulatory elements.
Data Source
AI summary
The present invention relates to nucleic acid regulatory elements that are able to enhance heart-and/or muscle-targeted expression of genes, in particular heart- and muscle-targeted gene expression, more particularly gene expression in cardiomyocytes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly heart- and/or muscle-directed gene therapy, e.g. for the treatment of cardiovascular diseases and disorders and muscle disorders, as well as other diseases and disorders that may benefit from high transgene expression in heart and/or muscle cells or tissue, and for vaccination purposes.